BioMedNewsBreaks

TuesdayNov 19, 2024 11:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Positive Data for Groundbreaking Technology at AHA Conference

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, today announced the results from two studies evaluating its groundbreaking vector-based technology. According to the announcement, the data add to the body of evidence for HeartBeam’s key clinical indications, specifically arrhythmia and heart attack (myocardial infarction) detection, and showcase the technology’s pivotal role in advancing patient care. The studies were presented during the American Heart Association’s annual Scientific Sessions in Chicago, Nov. 16-18, 2024. “The data presentations at AHA are a testament to HeartBeam’s dedication to building a robust…

Continue Reading

TuesdayNov 19, 2024 9:30 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $7.5 Million Through Public Stock Offering

Calidi Biotherapeutics (NYSE American: CLDI) announced the successful closing of a public offering of 4,437,869 shares of common stock at $1.69 per share, raising approximately $7.5 million in gross proceeds. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering, which was conducted under an effective registration statement on Form S-3 filed with the SEC. The final prospectus is available on the SEC’s website or through Ladenburg Thalmann. The offering complies with all relevant securities laws and regulations. To view the full press release, visit: https://ibn.fm/5LDBg About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that…

Continue Reading

MondayNov 18, 2024 11:51 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP) announced that its abstract on the pivotal trial of Berubicin, a novel treatment for glioblastoma multiforme (“GBM”), has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology. The presentation, led by Chief Medical Officer Dr. Sandra Silberman, will provide updates on the randomized, controlled CNS-201 trial comparing Berubicin to Lomustine after first-line GBM therapy. The session will take place on Nov. 22, 2024, at the George R. Brown Convention Center in Houston, TX, during the Poster and Networking Session. To view the full press release, visit https://ibn.fm/NjZCs About CNS Pharmaceuticals…

Continue Reading

MondayNov 18, 2024 11:26 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases RTNova Virotherapy Breakthrough for Metastatic Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) presented data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting highlighting its RTNova™ systemic virotherapy technology. This innovative platform leverages a tumor-selective vaccinia virus enhanced with extracellular enveloped viruses (“EEVs”) to overcome challenges like immune clearance and limited targeting in systemic virotherapy. RTNova demonstrated potential to target and kill metastatic tumor sites across multiple oncology indications, including metastatic lung cancer, while transforming tumor microenvironments and delivering therapeutic payloads. These findings position RTNova as a groundbreaking approach for addressing advanced metastatic diseases, supporting Calidi’s mission to develop multi-modal, off-the-shelf…

Continue Reading

MondayNov 18, 2024 8:45 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Expands OPKO Product Promotion at Asia’s Largest Health Expo in China

NextPlat (NASDAQ: NXPL, NXPLW) announced its participation in the 2024 China International Natural Health & Nutrition Expo (“NHNE”) in Wuhan, showcasing OPKO Health Europe products, including new veterinary and animal care offerings. Supported by its in-country marketing partner, NextPlat has seen increasing demand for OPKO products in China, fueled by online and offline promotional campaigns. The company is leveraging NHNE to connect with thousands of potential retail and distribution partners while launching OPKO storefronts on major Chinese platforms like WeChat and JD.com. NextPlat aims to secure broader physical distribution in major retail chains by 2025, advancing its strategy to capitalize…

Continue Reading

FridayNov 15, 2024 2:15 pm

BioMedNewsBreaks — Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) Marks Tremendous Milestone with $50M Public Offering

Alpha Cognition (NASDAQ: ACOG) (CSE: ACOG), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, recently announced the pricing of its upsized public offering of 8,695,653 common shares, each at a public offering price of $5.75, for gross proceeds of approximately $50 million. In addition, the company granted the underwriters a 30-day option to purchase up to an additional 1,184,592 common shares to cover over-allotments at the public offering price, less the underwriting discount. Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering. “This offering serves as a tremendous…

Continue Reading

FridayNov 15, 2024 9:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position

CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent glioblastoma multiforme (“GBM”). Enrollment of 252 patients was completed, with primary analysis data expected in the first half of 2025. Berubicin, which crosses the blood-brain barrier, has received Fast Track and Orphan Drug Designations from the FDA. The company also licensed TPI 287, a late-stage candidate for brain malignancies, with plans for FDA engagement on future studies. CNS ended the quarter with $7.0 million in cash and additional funding, ensuring operations through Q2 2025.…

Continue Reading

FridayNov 15, 2024 9:10 am

BioMedNewsBreaks – HealthLynked Corp. Restructures for Growth, Reports Declines in Revenue and Increased Losses in Q3 2024

HealthLynked (OTCQB: HLYK) has announced its Q3 2024 financial results, reflecting a strategic shift toward software solutions and a leaner operational model. Revenue dropped 56% year-over-year to $0.59 million, attributed to disruptions from clinical restructuring efforts, while operating expenses fell 10% in Q3 and 19% year-to-date due to efficiency initiatives. However, the company reported a $1.97 million net loss for the quarter, primarily due to the absence of a one-time $1.08 million gain recorded in 2023. HealthLynked is pivoting away from traditional clinical operations, focusing on app-based services to expand its user base and enhance operational scalability. To view the…

Continue Reading

ThursdayNov 14, 2024 8:00 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Reports Q3 Financials, Highlights Growth from Progressive Care and Outfitter Satellite Acquisitions

NextPlat (NASDAQ: NXPL, NXPLW)  reported Q3 2024 results reflecting the impact of its recent acquisitions, including Progressive Care and Outfitter Satellite, which contributed to consolidated revenues of $15.4 million. While healthcare revenue declined due to lower prescription reimbursement rates, e-Commerce revenue saw a 31% increase, largely from the Outfitter acquisition. The company recorded a net loss of $4.2 million due to increased expenses, including a non-cash impairment of Progressive Care’s intangible assets. Recent developments include expanding healthcare contracts and satellite communication device sales, along with a strengthened e-commerce presence in China and the UK. NextPlat projects ongoing growth from integration…

Continue Reading

WednesdayNov 13, 2024 2:28 pm

BioMedNewsBreaks — Astiva Health Earns Prestigious 4-Star CMS Rating

Astiva Health, a fast-growing leader in culturally responsive Medicare Advantage Prescription Drug (“MAPD”) health plans, today announced that it has earned a 4-star rating from the Centers for Medicare & Medicaid Services (“CMS”) for 2025. The CMS rating system evaluates Medicare Advantage (“Part C”) and Prescription Drug (“Part D”) plans on more than 40 quality and performance measures. The notable achievement highlights Astiva Health’s commitment to delivering high-quality, personalized healthcare, particularly to underserved populations across Southern California. "We are very proud to have earned this 4-star rating from CMS in just our first few years of operation," said Dr. Tri…

Continue Reading